8. CLABSI, VAP/VAE & CAUTI Prevention Bundles

Quick Recap

Cross-cutting supportive-care protocol — part of the daily ICU bundle. Consolidates the three device-associated healthcare-associated infection (HAI) prevention domains — CLABSI, VAP/VAE, and CAUTI — grounded in the SHEA/IDSA/APIC/AHA/Joint Commission Compendium 2022–2023 updates, which contain several genuinely counterintuitive reversals from older, still-widely-practiced habits.

1. Definition

CLABSI (Central Line-Associated Bloodstream Infection): a bloodstream infection in a patient with a central venous catheter in place (or removed within 48 hours) that is not related to an infection at another site.

VAP (Ventilator-Associated Pneumonia): pneumonia developing in a mechanically ventilated patient, historically diagnosed by clinical/radiographic criteria that are increasingly recognized as subjective and non-specific.

VAE (Ventilator-Associated Event): an objective, surveillance-oriented framework (sustained increase in ventilator settings after a period of stability, plus infection/inflammation criteria) developed specifically because VAP diagnosis is unreliable for surveillance purposes — VAE is not synonymous with VAP: only approximately 25–33% of VAEs are actually due to pneumonia, and many mild pneumonias do not meet VAE criteria at all. This distinction matters clinically, not just for surveillance semantics.

NV-HAP (Non-Ventilator Hospital-Acquired Pneumonia): pneumonia in a non-ventilated hospitalized patient — now explicitly included alongside VAP/VAE in the current compendium, reflecting recognition that pneumonia risk and prevention strategy are not exclusively a ventilator-associated problem.

CAUTI (Catheter-Associated Urinary Tract Infection): a UTI in a patient with an indwelling urinary catheter in place (or removed within 48 hours).

2. Pathophysiology

CLABSI: organisms gain access to the bloodstream via the catheter lumen (intraluminal contamination, typically from hub manipulation) or the catheter's external surface (extraluminal, from skin flora migrating along the catheter track) — this dual mechanism is why prevention bundles address both insertion-site skin antisepsis and ongoing catheter/hub-handling practices, not just one or the other.

VAP/VAE: the endotracheal tube bypasses normal upper-airway defenses and provides a direct conduit for oropharyngeal secretions (often colonized by nosocomial organisms) to reach the lower respiratory tract, particularly via micro-aspiration around the endotracheal tube cuff; supine positioning and impaired cough/mucociliary clearance compound this risk.

CAUTI: the catheter provides both a direct conduit for ascending bacterial migration into the bladder and disrupts normal bladder emptying/flushing mechanisms; daily bacteriuria risk with an indwelling catheter is 3–7% per day, making duration of catheterization the single most significant, and most modifiable, risk factor — this is the central organizing principle of CAUTI prevention.

3. Immediate Stabilization (ABCDE) — Device-Associated Infection Prevention as a Bundle

Not an acute stabilization scenario; functions as a daily, device-by-device verification checklist:

Checklist — reviewed for every indwelling device, every day:

4. Focused History

• Indication and insertion date for each indwelling device (central line, endotracheal tube, urinary catheter)
• Ongoing indication reassessed against accepted criteria, not the original admission indication alone (indications change over the course of an ICU stay)
• Prior HAI history this admission (informs heightened surveillance)
• Aspiration risk factors (relevant to VAP prevention approach, including postpyloric feeding consideration in high-risk patients)

5. Comprehensive System-wise Examination

• Vascular access sites: dressing integrity, signs of local infection, catheter necessity
• Airway/oral cavity: oral hygiene status, secretion burden
• Genitourinary: catheter necessity, signs of local trauma/obstruction (a non-infectious catheter harm the current compendium explicitly tracks alongside infection)

POCUS integration: not a primary component of device-associated infection prevention; relevant only if investigating a specific complication (e.g., line-associated thrombosis).

6. Syndrome Identification — Not Applicable in the Traditional Sense

This protocol is preventive/process-oriented rather than diagnostic; cross-reference relevant disease-specific protocols (Septic Shock, Severe Pneumonia) if an actual device-associated infection is suspected or confirmed.

7. Differential Diagnosis — Reframed as "Is This Device Still Necessary?"

For each device type, the compendium-endorsed accepted indications should be checked explicitly, not assumed:

Central line — accepted ongoing indications: vasopressor/inotrope infusion, hemodynamic monitoring requirement, need for multiple incompatible infusions, poor peripheral access with ongoing IV therapy need, hemodialysis/CRRT access.

Urinary catheter — accepted ongoing indications: accurate urine output monitoring in a hemodynamically unstable/critically ill patient, acute urinary retention/obstruction, perioperative use for specific procedures, stage 3–4 pressure injury with incontinence complicating wound care, patient comfort at end of life. Not an accepted indication: nursing/staff convenience, patient/family request alone without a clinical indication, incontinence management in an otherwise mobile patient (alternatives exist — Section 11).

Endotracheal tube: indication reassessed via standard extubation-readiness criteria (cross-reference Post-Extubation Failure & Reintubation protocol) — the relevant "differential" here is continued ventilatory necessity, not infection risk per se, though prolonged unnecessary intubation directly compounds VAP/VAE risk.

8. Severity/Risk Assessment

CLABSI risk: catheter dwell time, insertion site (subclavian now preferred — Section 11), lumen number, hub-access frequency.

VAP/VAE risk: duration of mechanical ventilation, aspiration risk factors, sedation depth (cross-reference Pain Assessment & Sedation Strategy protocol — oversedation directly compounds VAE risk via prolonged ventilation and impaired airway clearance).

CAUTI risk: duration of catheterization is the dominant, most modifiable risk factor — daily bacteriuria risk 3–7%; approximately 50% of urinary catheters in hospitalized patients may not be necessary, and roughly 40% of CAUTIs are directly attributable to catheter presence — these are large, actionable numbers that should inform daily practice, not abstract statistics.

9. Investigations

Not primarily a diagnostic workup; relevant surveillance metrics (tracked at the institutional/unit level per Section 16) include device-days, device-utilization ratios, and infection rates per device-day — process measures that should be reviewed regularly as a quality signal, not only when an individual infection is suspected.

10. Point-of-Care Ultrasound

Not a primary component of this protocol.

11. Evidence-Based Management — Current SHEA/IDSA/APIC Compendium (2022–2023 Updates)

CLABSI Prevention — Key Updates From the 2022 Compendium

• Subclavian vein is now the preferred insertion site for central venous catheters in ICU patients specifically to reduce infectious complications (a change in emphasis reflecting accumulated comparative evidence)
• Chlorhexidine-containing dressings are now an essential practice (previously classified only as an "additional approach" reserved for units with persistently high CLABSI rates in the 2014 guidance) — this is a genuine upgrade in recommendation strength, not a minor update
• Daily chlorhexidine bathing for ICU patients >2 months of age (high-quality evidence)
• Administration set replacement interval extended: non-blood/lipid administration sets can now be replaced at intervals of up to 7 days (previously up to 4 days) — a practical, evidence-supported simplification reducing unnecessary line manipulation (and thus infection risk) without compromising safety
• Daily review of central line necessity remains foundational — the single most consistently endorsed CLABSI prevention practice across every iteration of this guidance

VAP/VAE/NV-HAP Prevention — Key Updates From the 2022 Compendium, Including a Genuine Reversal

• The compendium now recommends AGAINST including chlorhexidine in oral care regimens — this is a significant, counterintuitive reversal from a practice that had been widespread for years based on earlier, smaller studies; accumulated evidence did not support a net benefit and raised concerns the practice may not be net-beneficial
• Tooth-brushing-based oral care, not chlorhexidine/gauze wipes, is the current evidence-preferred approach — a 2023–2024 quality improvement study replacing chlorhexidine/gauze oral care with structured tooth-brushing (2 minutes, silicone toothbrush, teeth/airway/tongue/palate) found VAP incidence fell from 3.9 to 2.4 per 1,000 ventilator-days (IRR 0.62, 95% CI 0.45–0.86, p=0.007), including reduced VAP from organisms classically isolated from dental plaque (Klebsiella pneumoniae, Acinetobacter baumannii, Pseudomonas aeruginosa)
• Subglottic secretion drainage endotracheal tubes reclassified from an essential practice to an additional approach for adults and older children — reflecting that the evidence for routine, universal use is less compelling than previously framed; still reasonable to consider, but no longer a default expectation
• Consider early tracheostomy in appropriate patients (added recommendation)
• Consider postpyloric (rather than gastric) feeding specifically in patients at high aspiration risk (added recommendation)
• Head-of-bed elevation (typically 30–45°) remains a foundational, low-cost, low-risk practice — a 2023 quality improvement intervention reinforcing HOBE indications/monitoring alongside the oral care change found meaningful VAP incidence reduction
• Daily sedation interruption and spontaneous breathing trial remain foundational to minimizing ventilator duration itself (cross-reference Pain Assessment & Sedation Strategy and Post-Extubation Failure & Reintubation protocols — shorter ventilator duration is itself the most direct VAE/VAP risk reduction strategy)
• Selective digestive decontamination: remains a debated, unresolved "thorniest issue" explicitly flagged by the compendium panel itself — not a settled essential practice

CAUTI Prevention — Key Updates From the 2022 Compendium

• Avoid unnecessary catheter placement and remove promptly when no longer needed — this remains the single most important, most emphasized intervention, restated even more explicitly in the current update
• Daily, institution-wide review of catheter necessity against accepted indication criteria (Section 7), ideally supported by electronic or other reminder systems, is an essential practice
• Consider alternatives to indwelling catheters before placement: intermittent (straight) catheterization, non-catheter incontinence management supplies, external/condom catheters — explicitly recommended as first-line consideration, not merely a fallback
• Do NOT routinely use antimicrobial- or antiseptic-impregnated catheters — explicitly recommended against as a routine practice
• Do NOT routinely screen for asymptomatic bacteriuria — explicitly recommended against; screening in the absence of symptoms drives unnecessary antibiotic use without clinical benefit
• Unresolved/unsettled issues explicitly acknowledged by the compendium: choice of antiseptic solution vs. sterile saline for pre-insertion cleaning, and routine catheter replacement intervals beyond 30 days — genuinely open questions, not areas of settled guidance
• Track catheter harms beyond infection: obstruction, unintended removal, catheter trauma, reinsertion within 24 hours of removal — the current compendium explicitly broadens the outcome focus beyond CAUTI alone to overall catheter-related harm

Practical Synthesis

The unifying principle across all three domains is the same: the most powerful intervention is not having the device in the first place, or removing it as soon as it is no longer necessary — daily necessity review is the single practice that appears as foundational, essential guidance across CLABSI, VAP/VAE, and CAUTI alike. Beyond that shared principle, clinicians should specifically update practice around two genuine reversals that may not yet be reflected in local protocols: chlorhexidine oral care is no longer recommended for VAP prevention (replace with structured tooth-brushing), and subglottic secretion drainage tubes are no longer a default essential practice (though still reasonable to consider selectively).

12. Organ Support

Not directly an organ-support topic; interacts with mechanical ventilation duration (cross-reference Pain Assessment & Sedation Strategy and Post-Extubation Failure & Reintubation protocols, since minimizing ventilator duration is itself the most direct VAP/VAE prevention strategy) and with renal replacement therapy access (central line necessity in CRRT patients).

13. Disease-Specific Therapy — Not Applicable

This is a prevention/process protocol; cross-reference Septic Shock or Severe Pneumonia protocols for treatment of an actual confirmed device-associated infection.

14. Consultation Matrix

15. Monitoring Framework

• Institutional/unit-level surveillance: device-days, device-utilization ratio, infection rate per device-day for each of CLABSI, VAP/VAE, CAUTI — tracked as ongoing quality metrics, reviewed regularly (cross-reference the "next frontier" surveillance literature explicitly noting a need to look beyond device-associated infection metrics alone toward broader HAI/harm measurement)
• Bedside/daily: explicit device-necessity review for every indwelling device, every day, ideally embedded into daily rounds structure rather than relying on individual clinician memory
• Escalation triggers: rising unit-level infection rates → trigger consideration of "additional approaches" beyond essential practices per compendium framework

16. ICU Bundle Checklist (Daily)

17. Complications

Early:

• CLABSI, VAP, CAUTI themselves — each associated with increased morbidity, mortality, length of stay, and cost (CLABSI alone associated with ~$32,000 higher adjusted variable cost per patient in cited cost data)
• Non-infectious device harms: catheter trauma, obstruction, unintended removal (explicitly tracked in the current CAUTI compendium as harms distinct from infection)

Late:

• Prolonged hospitalization and downstream complications from a preventable HAI
• Antimicrobial resistance pressure from treatment of preventable infections

Prevention: the entire content of Section 11 — daily necessity review is the unifying, most powerful preventive practice across all three device types

Rescue: prompt device removal/exchange and infectious disease-guided treatment once an infection is confirmed; cross-reference relevant treatment protocols

18. Escalation & De-escalation

Escalation: confirmed device-associated infection → cross-reference relevant treatment protocol (Septic Shock, Severe Pneumonia); consider device removal/exchange as part of source control (cross-reference Sepsis Bundles & Source Control protocol).

De-escalation: device removed as soon as necessity criteria are no longer met — this is the primary "de-escalation" action in this protocol, and should be pursued proactively rather than reactively.

19. ICU Discharge Criteria (Device-Relevant Context)

Cross-reference ICU Discharge Criteria & Step-Down protocol. Device-specific consideration: every indwelling device reviewed explicitly before transfer — remove anything no longer necessary rather than transferring an unnecessary device to a lower-monitoring-intensity setting where necessity review may be less rigorous.

20. Documentation & Medicolegal Checklist

• Daily device-necessity review documented for every indwelling device (central line, endotracheal tube, urinary catheter)
• Rationale documented for any device retained beyond typical expected duration
• Insertion-site/technique documented per current compendium standards (e.g., subclavian preference, chlorhexidine dressing use)
• Oral care regimen documented (tooth-brushing-based, not chlorhexidine, per current evidence)
• Any device-associated infection documented with full workup and management per relevant treatment protocol

21. Key Guidelines

• Buetti N, Marschall J, Drees M, et al. Strategies to prevent central line-associated bloodstream infections in acute-care hospitals: 2022 Update. Infect Control Hosp Epidemiol. 2022;43(5):553-569.
• Klompas M, Branson R, Cawcutt K, et al. Strategies to prevent ventilator-associated pneumonia, ventilator-associated events, and nonventilator hospital-acquired pneumonia in acute-care hospitals: 2022 Update. Infect Control Hosp Epidemiol. 2022;43(6):687-713.
• Patel PK, Advani SD, Kofman AD, et al. Strategies to prevent catheter-associated urinary tract infections in acute-care hospitals: 2022 Update. Infect Control Hosp Epidemiol. 2023;44(8):1209-1231.
• All three are part of the Compendium of Strategies to Prevent Healthcare-Associated Infections in Acute Care Hospitals, a collaborative effort of SHEA, IDSA, APIC, AHA, The Joint Commission, and CDC — the current authoritative source for all three domains covered in this protocol

22. Landmark Trials / Key Evidence

23. Controversies

• Selective digestive decontamination (SDD): explicitly flagged by the VAP/VAE compendium panel itself as one of the genuinely unresolved "thorniest issues" — not adopted as essential guidance despite some supportive trial data, reflecting ongoing debate about generalizability, antimicrobial resistance concerns, and applicability outside specific study settings.
• VAE surveillance vs. clinical VAP diagnosis: the deliberate move toward VAE as an objective surveillance metric acknowledges that clinical VAP diagnosis is subjective and non-specific — but this means VAE rates and VAP rates are measuring meaningfully different things (only ~25–33% of VAEs are pneumonia), and clinicians/institutions should be careful not to conflate VAE surveillance data with actual pneumonia burden when interpreting quality metrics.
• CAUTI unresolved issues, explicitly acknowledged by the compendium itself: choice of antiseptic vs. sterile saline for pre-insertion cleaning, and optimal routine catheter replacement interval beyond 30 days — genuinely open questions rather than settled guidance, worth not overstating certainty on.
• Adjunctive practices requiring further study: the compendium explicitly notes several areas (e.g., certain CLABSI adjuncts in specific populations, SDD) as requiring further research rather than being ready for essential-practice status — institutions should distinguish clearly between "essential practice" (should be adopted everywhere) and "additional approach" (consider if rates remain elevated despite essential practices) rather than treating the entire compendium as uniformly mandatory.
• Surveillance metric evolution: recent literature explicitly calls for HAI surveillance to move "beyond device-associated infections" toward broader harm measurement — signaling that even the current device-centric framework (CLABSI/VAP/CAUTI as the primary metrics) may itself evolve further in coming years.

24. References

1. Buetti N, Marschall J, Drees M, et al. Strategies to prevent central line-associated bloodstream infections in acute-care hospitals: 2022 Update. Infect Control Hosp Epidemiol. 2022;43(5):553-569.
2. Klompas M, Branson R, Cawcutt K, et al. Strategies to prevent ventilator-associated pneumonia, ventilator-associated events, and nonventilator hospital-acquired pneumonia in acute-care hospitals: 2022 Update. Infect Control Hosp Epidemiol. 2022;43(6):687-713.
3. Patel PK, Advani SD, Kofman AD, et al. Strategies to prevent catheter-associated urinary tract infections in acute-care hospitals: 2022 Update. Infect Control Hosp Epidemiol. 2023;44(8):1209-1231.
4. Advani SD, Cawcutt K, Klompas M, Marschall J, Meddings J, Patel PK. The next frontier of healthcare-associated infection (HAI) surveillance metrics: beyond device-associated infections. Infect Control Hosp Epidemiol. 2024:1-5.
5. [Oral care enhancement QI study] Evaluation of head elevation and oral care enhancement activity in intensive care units to prevent ventilator-associated pneumonia. 2023-2024.
6. Classen DC, Rhee C, Dantes RB, Benin AL. Healthcare-associated infections and conditions in the era of digital measurement. Infect Control Hosp Epidemiol. 2024;45(1):3-8.
7. The Washington Manual of Critical Care, 4th ed. 2025 — relevant infection prevention content.
8. ICU Protocols: A Step-wise Approach, 2nd ed. — infection control chapter.